Answers are grounded in this paper and cite their sources.
Prostate cancer treatment commonly involves chemotherapy, radiation, and surgery, but systemic administration of cytotoxic agents is limited by dose-limiting toxicities. Localized delivery strategies may overcome these limitations. We evaluated the feasibility of a novel intra-prostatic docetaxel sustained-release implant (InCeRT-DTX) combined with external beam radiation therapy (EBRT) in a large animal model. Nineteen beagle dogs with benign prostatic hyperplasia (BPH) received surgical implantation of InCeRT-DTX into the prostate. A subset also underwent a single 16 Gy dose of EBRT. Pharmacokinetics, safety, local toxicity, and therapeutic responses were assessed by serum analysis, imaging, and histopathology. The tolerated intra-prostatic docetaxel dose was 9 µg per cm³ of prostate volume—over 10-fold higher than the estimated dose achievable by intravenous delivery in humans. At this dose, no systemic toxicities were observed, and local effects were minimal and non-clinical. Implants alone produced negligible changes in prostate morphology; however, the combination of InCeRT-DTX with EBRT resulted in a 38–45% reduction in prostate volume. Histopathological analysis showed limited necrosis and fibrosis localized to the implant site, while increased apoptotic activity suggested apoptosis as a primary mechanism of glandular shrinkage. Localized delivery of docetaxel via InCeRT-DTX implants enables safe administration of high intra-prostatic doses without systemic toxicity. When combined with EBRT, this approach produces significant prostate volume reduction, indicating a synergistic therapeutic effect. These findings support the translational potential of “inside-out” chemotherapy as a novel prostate cancer treatment strategy.
No takes yet. Share an insight, caveat, or question.
Kheirollah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: